ARTAN Bio Closes $1 Million Seed Round to Advance its tRNA Platform Toward Human Studies
Financing follows Torres's CrossBridge Bio acquisition by Eli Lilly and supports translation of ARTAN Bio's programmable approach to mutation-driven aging biology ST. PETERSBURG, Fla., July 1, 2026 /PRNewswire/ -- ARTAN Bio, a longevity biotechnology company based in St. Petersburg,...
Financing follows Torres's CrossBridge Bio acquisition by Eli Lilly and supports translation of ARTAN Bio's programmable approach to mutation-driven aging biology ST. PETERSBURG, Fla., July 1, 2026 /PRNewswire/ -- ARTAN Bio, a longevity biotechnology company based in St. Petersburg,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.